QPPV.COM KNOWLEDGE ASSESSMENT

Professional Knowledge Assessment: Article 30 Referral in EU Medicines Regulation

Test your understanding of the concepts covered by Article 30 Referral in EU Medicines Regulation: Divergent National Decisions and Harmonisation.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement correctly distinguishes the CHMP opinion from the European Commission decision?

The CHMP opinion is the legally binding national implementation instrument The Commission decision is merely advisory, while the CHMP opinion binds Member States The CHMP opinion is the committee's scientific conclusion, while the Commission decision establishes the binding Union outcome addressed to Member States They are interchangeable documents with identical legal functions

Question 2 of 10 An Article 30 referral changes a contraindication and strengthens a warning. Which QPPV action is most appropriate?

Take no action because Article 30 is not itself a pharmacovigilance referral Ensure a documented pharmacovigilance impact assessment and coordinate updates to relevant safety systems and risk-management processes Replace the Commission decision with a new company safety position Wait until a new safety referral is opened before reviewing the change

Question 3 of 10 What is the consequence if a re-examination request is withdrawn?

The initial CHMP opinion immediately becomes the final opinion The Commission automatically reopens the scientific assessment The referral is permanently cancelled and all national authorisations lapse A new Article 30 referral is automatically initiated

Question 4 of 10 Which statement best distinguishes Article 30 from Article 29(4)?

Article 30 concerns unresolved MRP or DCP disagreements, whereas Article 29(4) concerns historical national decisions Article 30 is a pharmacovigilance procedure, whereas Article 29(4) is a quality procedure Article 30 addresses existing divergent national decisions, whereas Article 29(4) escalates an unresolved MRP or DCP disagreement involving a potential serious risk to public health Article 30 is initiated only by the Commission, whereas Article 29(4) is initiated only by an MAH

Question 5 of 10 Which description most accurately differentiates Article 30 from an Article 31 pharmacovigilance referral?

Article 30 is defined by divergent national decisions, while Article 31 may be based on a Union-interest quality, safety or efficacy concern and has a specific pharmacovigilance pathway Article 30 always involves PRAC first, while Article 31 always involves CMDh first Article 31 applies only to centrally authorised products, while Article 30 applies only to investigational products There is no meaningful legal distinction because both procedures involve CHMP

Question 6 of 10 A later variation concerns the same SmPC section that was harmonised through Article 30. What is the best regulatory control?

Use the pre-referral wording because it was historically approved in one Member State Assess the variation against the final harmonised product-information baseline and recognise the Article 30 regulatory history Ignore the Article 30 outcome once national implementation is complete Assume that any later variation automatically reverses the Commission decision

Question 7 of 10 What is the primary procedural function of the formal referral notification?

It automatically approves the MAH's proposed harmonised wording It defines the legal basis, products, national authorisations, divergence and issues to be examined It replaces the later Commission decision It closes all national procedures affecting the product

Question 8 of 10 How should the scope of products and authorisations in an Article 30 referral be established?

By including every product commercially marketed by the MAH in the EU By relying solely on the company's current product catalogue By reviewing the relevant national regulatory record and confirming affected presentations and authorisations with authorities By limiting scope to the strongest presentation in the reference Member State

Question 9 of 10 Which conclusion about post-referral activity is most consistent with the article?

All regulatory surveillance can stop once the Commission decision is published The Article 30 outcome becomes part of continuing regulatory history and should be considered in later safety, efficacy and lifecycle assessments Any later safety concern must be handled through another Article 30 referral Post-referral monitoring is relevant only to quality departments

Question 10 of 10 Which implementation package would best support inspection readiness after an Article 30 referral?

Only the final press release and the current package leaflet A controlled record linking the divergence, referral documents, questions, responses, opinions, decision, translations and national implementation evidence Only meeting minutes from the CHMP plenary A list of affected countries without dates or supporting documents

Professional Knowledge Assessment: Article 30 Referral in EU Medicines Regulation

Cookie Settings